Jobs at Curi Bio

The cost to develop a single new drug has increased 100-fold since the 1950’s. Preclinical models often fail to predict human drug responses, contributing to an overall >80% failure rate of clinical trials, a primary driver of high drug development costs. Curi Bio has developed an integrated discovery engine leveraging human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics to accelerate the discovery and development of the next generation of medicines. Curi gives pharmaceutical companies access to human-relevant preclinical data at the earliest stages of development, improving the prediction of safety and efficacy of novel therapeutics, eliminating unsafe candidates early, and reducing industry reliance on poorly-predictive animal models. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. Curi integrates human iPSC-derived cell models into innovative tissue-specific biosystems to generate clinically-relevant functional data from engineered tissues. Curi analyzes cell-based assay data using its proprietary AI and deep-learning platform to enable highly predictive phenotypic drug screening.